Skip to main content
Fig. 1 | BMC Gastroenterology

Fig. 1

From: ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma

Fig. 1

ARID1A loss-of-function mutations and copy number deletions correlated with ARID1A deficiency and were associated with worse overall survival in HBV-related HCC. a Mutation status of the top 20 mutated genes, including ARID1A, is presented in all three cohorts. Patients were grouped according to the mutations in ARID1A. The histogram on top shows the number of nonsynonymous mutations in each patient. The histogram on the right shows the number of mutations in each gene. Clinical characteristics are plotted at the bottom. b, c ARID1A mRNA showed no significant difference between the two groups. At the same time, the protein expression of ARID1A was significantly higher in the normal functioning group; expression and protein level are log-transformed. d, e HBV-related HCC patients with ARID1A deficiency were associated with cirrhosis and had worse overall survival. (* P < 0.05, ** P < 0.01, *** P < 0.001)

Back to article page